E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Cystic fibrosis Chronic Pseudomonas Aeruginosa Infection |
Fibrosis quística Infección crónica por Pseudomonas aeruginosa |
|
E.1.1.1 | Medical condition in easily understood language |
Chronic lung infection with Pseudomonas bacteria in adults with cystic fibrosis |
Infección pulmonar crónica por bacterias Pseudomonas en adultos con fibrosis quística |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10011763 |
E.1.2 | Term | Cystic fibrosis lung |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 22.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10082869 |
E.1.2 | Term | Chronic Pseudomonas aeruginosa infection |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the safety and tolerability of nebulized BX004-A in CF subjects with chronic PsA pulmonary infection. |
Evaluar la seguridad y la tolerabilidad de BX004-A nebulizado en sujetos con FQ con infección pulmonar crónica por PsA |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infection receiving standard of care CF medications 2. Age ≥ 18 years 3. FEV1 ≥ 40% predicted 4. Clinically stable lung disease 5. Willing and able to provide adequate sputum samples, using any method (spontaneously expectorated, induced, from home or clinic) at designated study visits. |
1. Pacientes con fibrosis quística e infección pulmonar crónica por Pseudomonas aeruginosa que reciben medicamentos estándar para la FQ 2. Edad ≥ 18 años 3. FEV1 ≥ 40% previsto 4. Enfermedad pulmonar clínicamente estable 5. Estar dispuesto y ser capaz de proporcionar muestras de esputo adecuadas , utilizando cualquier método (expectoradas espontáneamente, inducido, en el hogar o en la clínica) en las visitas de estudio designadas. |
|
E.4 | Principal exclusion criteria |
1. Known hypersensitivity to bacteriophages or excipients in the formulation. 2. Receipt of prior bacteriophage therapy within the 6 months prior to Screening 3. Recovery of Burkholderia species from respiratory tract within 1 year prior to screening 4. Currently receiving treatment for allergic bronchopulmonary aspergillosis 5. Currently receiving treatment for active infection with non-tuberculous mycobacteria 6. History of severe neutropenia 7. History of lung transplant 8. History of solid organ transplant 9. Acquired or primary immunodeficiency syndrome 10. Initiation or change in CF modulator therapy less than 3 months prior to screening 11. Pregnant or breastfeeding female |
1. Hipersensibilidad conocida a bacteriófagos o a los excipientes de la formulación. 2. Recepción de terapia con bacteriófago previa en los 6 meses anteriores a la selección 3. Recuperación de cualquier especie de Burkholderia de las vías respiratorias en el plazo de 1 año antes de la selección 4. Estar recibiendo en la actualidad tratamiento para la aspergilosis broncopulmonar alérgica 5. Estar recibiendo en la actualidad tratamiento para la infección activa con micobacterias no tuberculosas 6. Antecedentes de neutropenia grave 7. Antecedentes de trasplante de pulmón 8. Antecedentes de trasplante de órgano sólido 9. Síndrome de inmunodeficiencia adquirida o primaria 10. Inicio o cambio en el tratamiento modulador de la FQ menos de 3 meses antes de la selección 11. Mujeres embarazadas o en periodo de lactancia |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety and tolerability, as assessed by vital sign measurements, pulmonary examination, laboratory tests, spirometry and adverse events |
Seguridad y tolerabilidad, evaluadas mediante mediciones de signos vitales, examen pulmonar, pruebas de laboratorio, espirometría y eventos adversos |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Safety will be assessed at every clinic visit: D1, D2, D3, D4, D8, D15 (also D35 phone call and 6 month phone call) |
La seguridad se evaluará en cada visita a la clínica: D1, D2, D3, D4, D8, D15 (también llamada telefónica D35 y llamada telefónica de 6 meses) |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 5 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Israel |
United States |
Netherlands |
Spain |
Czechia |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
6-month post last dose phone call |
Llamada telefónica 6 meses después de la última dosis |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 20 |